LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Начало・Списък с акции・Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

41.02 -0.12

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

41.02

Максимум

41.02

Ключови измерители
By Trading Economics
Приходи	100M 19M
Продажби	68M 268M
P/E Средно за сектора	38.337 51.415
EPS	0.15
Марж на печалбата	6.954
Служители	733
EBITDA	74M 27M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	-3.51% downside

Дивиденти
By Dow Jones
Следващи печалби	30.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	6.4M 5.3B
Предишно отваряне	41.14
Предишно затваряне	41.02

Настроения в новините

By Acuity

83%

17%

325 / 346 Класиране в Healthcare

Apellis Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.05.2026 г., 22:44 ч. UTC

Придобивния, сливания и поглъщания

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14.05.2026 г., 22:27 ч. UTC

Придобивния, сливания и поглъщания

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14.05.2026 г., 22:12 ч. UTC

Печалби

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14.05.2026 г., 21:52 ч. UTC

Придобивния, сливания и поглъщания

LVMH to Sell Marc Jacobs

15.05.2026 г., 00:00 ч. UTC

Печалби

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14.05.2026 г., 23:57 ч. UTC

Придобивния, сливания и поглъщания

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14.05.2026 г., 23:56 ч. UTC

Придобивния, сливания и поглъщания

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14.05.2026 г., 23:56 ч. UTC

Придобивния, сливания и поглъщания

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14.05.2026 г., 23:56 ч. UTC

Пазарно говорене

Gold Prices Rise on Strong Demand -- Market Talk

14.05.2026 г., 23:56 ч. UTC

Придобивния, сливания и поглъщания

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14.05.2026 г., 23:50 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

14.05.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14.05.2026 г., 23:47 ч. UTC

Печалби

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14.05.2026 г., 23:47 ч. UTC

Печалби

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14.05.2026 г., 23:46 ч. UTC

Печалби

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14.05.2026 г., 23:46 ч. UTC

Печалби

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14.05.2026 г., 23:28 ч. UTC

Пазарно говорене

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14.05.2026 г., 23:00 ч. UTC

Пазарно говорене

Australia's One Nation Party Leads In The Polls -- Market Talk

14.05.2026 г., 22:46 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

14.05.2026 г., 22:46 ч. UTC

Пазарно говорене

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14.05.2026 г., 22:46 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

14.05.2026 г., 22:35 ч. UTC

Пазарно говорене

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14.05.2026 г., 22:11 ч. UTC

Придобивния, сливания и поглъщания

LVMH Agrees to Sell Marc Jacobs -- WSJ

14.05.2026 г., 22:06 ч. UTC

Пазарно говорене

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14.05.2026 г., 22:04 ч. UTC

Печалби

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14.05.2026 г., 22:04 ч. UTC

Печалби

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14.05.2026 г., 22:04 ч. UTC

Печалби

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14.05.2026 г., 22:00 ч. UTC

Печалби

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14.05.2026 г., 21:55 ч. UTC

Печалби

Nu Holdings 1Q EPS 18c >NU

14.05.2026 г., 21:55 ч. UTC

Печалби

Nu Holdings 1Q Rev $4.97B >NU

Сравнение с други в отрасъла

Ценова промяна

Apellis Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

-3.51% надолу

12-месечна прогноза

Среден 39.59 USD -3.51%

Висок 41 USD

Нисък 28 USD

Според 19 анализатори от Wall Street, предложили 12-месечна ценова цел за Apellis Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

19 ratings

Купи

Задържане

Продай

Според 19 анализатори, дали борсови рейтинги на Apellis Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

325 / 346 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.